[Retracted] Amodiaquine-Artesunate versus Artemether-Lumefantrine against Uncomplicated Malaria in Children Less Than 14 Years in Ngaoundere, North Cameroon: Efficacy, Safety, and Baseline Drug Resistant Mutations in pfcrt, pfmdr1, and pfdhfr Genes

Table 4

Mean variation in haematological and biochemical indices 14 days after treatment.

Parameter	AS/AQ			AL
	𝑁	Mean ± SD	Paired 𝑡-test	𝑁	Mean ± SD	𝑃 value^+
Haematocrit (%)
D0	68	32.47±04.92		69	33.59±7.30
D14	68	32.58±05.31	0.87	69	33.24±5.33	0.66
WBCs (×10^3/𝜇L)
D0	68	11.04±06.72		69	12.78±14.88
D14	68	09.10±05.38	0.04*	69	08.70±4.13	0.026*
Platelets (×10^3/𝜇L)
D0	68	386.46±326.96		69	466.50±409.90
D14	68	650.94±508.88	0.001*	69	725.84±609.51	0.002*
ALAT (U/L)
D0	68	12.12±11.23		69	12.86±13.32
D14	68	10.20±08.03	0.25	69	10.52±6.49	0.17
Creatinine (mg/L)
D0	68	03.49±2.07		69	3.68±1.67
D14	68	03.92±2.01	0.17	69	4.51±2.69	0.019*
Bilirubin (mg/L)
D0	68	0.86±0.80		69	0.99±0.94
D14	68	0.87±0.86	0.95	69	0.86±0.94	0.43

Indices were measured at pre-treatment and on day 14. Values are reported as mean readings ± standard deviation of patients treated with AS/AQ or AL.
𝑁: number, SD: standard deviation, ALAT: alanine transaminase, and *significant at threshold of 𝑃=0.05. ⁺Paired students’ 𝑡-test.